<?xml version="1.0"?>
<case>
<name>Pfizer Corp v Commissioner of Patents [2006] FCA 164 (1 March 2006)</name>
<AustLII>http://www.austlii.edu.au/au/cases/cth/FCA/2006/164.html</AustLII>
<citphrases>
<citphrase id="cp0.0" type=cited from="[2005] FCA 1718">practice and procedure</citphrase>
<citphrase id="cp0.1" type=cited from="[2005] FCA 1718">joinder of parties</citphrase>
<citphrase id="cp0.2" type=cited from="[2005] FCA 1718">three proceedings in which patentee (l) a party</citphrase>
<citphrase id="cp0.3" type=cited from="[2005] FCA 1718">in first, another company (a) seeks revocation of patent, and an order rectifying register of patents accordingly, in the alternative an order removing an extension of term from the register</citphrase>
<citphrase id="cp0.4" type=cited from="[2005] FCA 1718">in second, l seeks against the commissioner of patents a declaration that reg 10.7(7) of the patents regulations 1991 (cth) is invalid</citphrase>
<citphrase id="cp0.5" type=cited from="[2005] FCA 1718">in third, l seeks order that secretary, department of health and ageing not use certain information provided to secretary by l in connection with application by a for registration of competing pharmaceutical substance</citphrase>
<citphrase id="cp0.6" type=cited from="[2005] FCA 1718">on a's motion to be joined as second respondent to the second proceeding, general principle that a should not be joined, subject to no issue of construction which a wished to advance in first (revocation) proceeding being raised and pre-empted in second (reg 10.7(7)) proceeding</citphrase>
<citphrase id="cp0.7" type=cited from="[2005] FCA 1718">on a's motion to be joined in third (secretary) proceeding, order for joinder made because of common issues and evidence as between this proceeding and first (revocation) proceeding.</citphrase>
<citphrase id="cp2.0" type=cited from="[1996] FCA 870">[ database search ] [ name search ] [ recent decisions ] [ noteup ] [ lawcite ] [ help ] news limited &amp; ors v australian rugby football league ltd &amp; ors; brisbane broncos rugby league football club ltd &amp; ors v australian rugby football league ltd &amp; ors; cowboys rugby league ltd v the australian rugby football club ltd &amp; ors [1996] fca 870 (4 october 1996)   practice and procedure</citphrase>
<citphrase id="cp2.1" type=cited from="[1996] FCA 870">appeals</citphrase>
<citphrase id="cp2.2" type=cited from="[1996] FCA 870">findings of primary facts</citphrase>
<citphrase id="cp2.3" type=cited from="[1996] FCA 870">review of inferences to be drawn from primary facts.</citphrase>
<citphrase id="cp3.0" type=cited from="[1992] FCA 198">intellectual property</citphrase>
<citphrase id="cp3.1" type=cited from="[1992] FCA 198">patents</citphrase>
<citphrase id="cp3.2" type=cited from="[1992] FCA 198">meaning and application of "new matter"</citphrase>
<citphrase id="cp3.3" type=cited from="[1992] FCA 198">whether discovery of the true structural formula constitutes new matter</citphrase>
<citphrase id="cp3.4" type=cited from="[1992] FCA 198">effect of new matter on priority dates</citphrase>
<citphrase id="cp3.5" type=cited from="[1992] FCA 198">application of fair basis</citphrase>
<citphrase id="cp3.6" type=cited from="[1992] FCA 198">role of commissioner for patents where no appearance on appeal</citphrase>
<citphrase id="cp3.7" type=cited from="[1992] FCA 198">right of appearance of commissioner for patents.</citphrase>
<citphrase id="cp4.0" type=cited from="[1980] HCA 13">broadcasting and television</citphrase>
<citphrase id="cp4.1" type=cited from="[1980] HCA 13">licence for commercial television</citphrase>
<citphrase id="cp4.2" type=cited from="[1980] HCA 13">prescribed interest held by company</citphrase>
<citphrase id="cp4.3" type=cited from="[1980] HCA 13">acquisition of shares by another company</citphrase>
<citphrase id="cp4.4" type=cited from="[1980] HCA 13">inquiry by australian broadcasting tribunal</citphrase>
<citphrase id="cp4.5" type=cited from="[1980] HCA 13">duty to investigate matters relevant to inquiry</citphrase>
<citphrase id="cp4.6" type=cited from="[1980] HCA 13">contraventions of act</citphrase>
<citphrase id="cp4.7" type=cited from="[1980] HCA 13">acquisition of beneficial entitlement to prescribed interest</citphrase>
<citphrase id="cp4.8" type=cited from="[1980] HCA 13">broadcasting and television act 1942 (cth), ss. 25, 91, 91a, 92 (1) (a), (2), (3) (a), 92f.  administrative bodies</citphrase>
<citphrase id="cp4.9" type=cited from="[1980] HCA 13">broadcasting</citphrase>
<citphrase id="cp4.10" type=cited from="[1980] HCA 13">supervisory authority</citphrase>
<citphrase id="cp4.11" type=cited from="[1980] HCA 13">inquiry</citphrase>
<citphrase id="cp4.12" type=cited from="[1980] HCA 13">procedure</citphrase>
<citphrase id="cp4.13" type=cited from="[1980] HCA 13">duty to investigate matters relevant to inquiry</citphrase>
<citphrase id="cp4.14" type=cited from="[1980] HCA 13">duty to summon evidence</citphrase>
<citphrase id="cp4.15" type=cited from="[1980] HCA 13">cross-examination of witnesses</citphrase>
<citphrase id="cp4.16" type=cited from="[1980] HCA 13">broadcasting and television act 1942 (cth), ss. 16 (1) (c), 25, 92f (4), (4a), 106a.</citphrase>
<citphrase id="cp5.0" type=citing from="[2006] FCA 1176">patents</citphrase>
<citphrase id="cp5.1" type=citing from="[2006] FCA 1176">date for calculation of extension of term of patents relating to pharmaceutical substances</citphrase>
<citphrase id="cp5.2" type=citing from="[2006] FCA 1176">"first inclusion in the australian register of therapeutic goods" not limited to regulatory approval to market pharmaceutical substance in australia</citphrase>
<citphrase id="cp5.3" type=citing from="[2006] FCA 1176">correct date if no "pre-tga marketing approval" granted is first entry in the australian register of therapeutic goods, including an entry as listed goods for export only statutory construction</citphrase>
<citphrase id="cp5.4" type=citing from="[2006] FCA 1176">extrinsic materials relevant to context and legislative history</citphrase>
<citphrase id="cp5.5" type=citing from="[2006] FCA 1176">materials equivocal on whether "first inclusion" means registration or listing</citphrase>
<citphrase id="cp5.6" type=citing from="[2006] FCA 1176">legislative objective that patentee should have "effective patent life" to exploit patent</citphrase>
</citphrases>
<citances>
<sentence id="cs0" from="[2006] FCA 1176">Spirit Pharmaceuticals Pty Limited is an Australian pharmaceutical company with a commercial interest in the expiry date of at least one of the Pfizer patents. Spirit was joined as a respondent to this proceeding on 1 March 2006 ( Pfizer Corp v Commissioner of Patents [2006] FCA 164 ; (2006) 67 IPR 646). </sentence>
</citances>
<legistitles>
<title id="l0">PATENTS ACT 1990 </title>
<title id="l1">PATENTS ACT 1990 - SECT 70 Applications for extension of patent</title>
<title id="l2">PATENTS ACT 1990 - SECT 75 Opposition to grant of extension</title>
<title id="l3">PATENTS ACT 1990 - SECT 107 Amendments directed by Commissioner: applications for standard patents</title>
<title id="l4">PATENTS ACT 1990 - SECT 128 Application for relief from unjustified threats</title>
<title id="l5">PATENTS ACT 1990 - SECT 192 Orders for rectification of Register</title>
<title id="l6">MIGRATION REGULATIONS 1994 </title>
</legistitles>
</case>